SCHEMBL282422

SCHEMBL282422

Nc1ccc(Oc2cncc3cc(N)ccc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 8/20 0.50
SELE P16581 8/20 0.50
VCAM1 P19320 4/20 0.50
CDK8 P49336 5/20 0.44
PIM1 P11309 2/20 0.44
MAP4K2 Q12851 2/20 0.44
MAP2K2 P36507 1/20 0.44
MAP3K8 P41279 1/20 0.43
MAP2K1 Q02750 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PRKCZ Q05513 3/20 0.39
KDM1A O60341 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
MITF O75030 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717713 0.83 ICAM1 (0.51) ICAM1SELEVCAM1CDK8PIM1
SCHEMBL10073789 0.80 CSF1R (0.57) ICAM1SELEVCAM1CDK8MAPT
SCHEMBL29024928 0.72 EGFR (0.47) ALDH1A1CYP3A4TSHRTDP1PRKCZ
SCHEMBL4724730 0.71 CYP19A1 (0.52) SMN1; SMN2GAAMAPTEGFRMAOA
SCHEMBL3060968 0.69 EGFR (0.44) ALDH1A1CYP3A4TSHRTDP1PRKCZ
SCHEMBL282060 0.69 EGFR (0.44) ICAM1SELEVCAM1ALDH1A1CYP3A4
SCHEMBL31325680 0.69 EGFR (0.44) ALDH1A1CYP3A4TSHRTDP1PRKCZ
SCHEMBL31325689 0.69 EGFR (0.44) ALDH1A1CYP3A4TSHRTDP1PRKCZ
SCHEMBL30644900 0.68 ALDH1A1 (0.58) ALDH1A1CYP3A4TSHRTDP1KDM1A
SCHEMBL21120581 0.68 MAOB (0.52) ALDH1A1CYP3A4TDP1KDM1ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 ICAM1 4649/4885SELE 2543/4885VCAM1 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.